1. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease
Torres et al. Am J Nephrol 2017;45:   (DOI: / )
Table 1. Eligibility requirements for REPRISE

2. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease
Torres et al. Am J Nephrol 2017;45:   (DOI: / )
Table 2. Study sites and number randomized

3. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease
Torres et al. Am J Nephrol 2017;45:   (DOI: / )
Fig. 1. REPRISE study schematic. F/U, follow-up. * Can be extended up to an additional 8 weeks for subjects needing stabilization after changing other treatments.